Shigematsu S
Second Department of Medicine, Kurume University School of Medicine, Japan.
Kurume Med J. 1998;45(2):175-9. doi: 10.2739/kurumemedj.45.175.
The therapeutic role of interleukin (IL)-1 receptor antagonist, a potent inhibitor of IL-1, was investigated using peripheral blood mononuclear cells from patients with ulcerative colitis and Crohn's disease. Administration of IL-1 receptor antagonist inhibited IL-1 beta-augmented IL-1 alpha and tumor necrosis factor-alpha production by mononuclear cells. Prednisolone caused a decrease in IL-1 receptor antagonist release, whereas sulfasalazine had no modulatory effect. Interestingly, IgG caused an increase in IL-1 receptor antagonist release. In conclusion, IL-1 receptor antagonist and related molecules may have therapeutic value.
使用溃疡性结肠炎和克罗恩病患者的外周血单核细胞，研究了白细胞介素（IL）-1受体拮抗剂（一种有效的IL-1抑制剂）的治疗作用。给予IL-1受体拮抗剂可抑制单核细胞产生IL-1β增强的IL-1α和肿瘤坏死因子-α。泼尼松龙导致IL-1受体拮抗剂释放减少，而柳氮磺胺吡啶无调节作用。有趣的是，IgG导致IL-1受体拮抗剂释放增加。总之，IL-1受体拮抗剂及相关分子可能具有治疗价值。
